Budget Impact Analysis of the Introduction of Injectable Prolonged-Release Buprenorphine on Opioid Use Disorder Care Resource Requirements
Helen Phillips-Jackson,1 Clive Hallam,2 Niamh Cullen,3 Terry Pearson,4 Mark Gilman,5 Li Li,6 Paul Musgrave7 1Working Group on Innovation Assessment, Expert Faculty on Commissioning, London, UK; 2Richmond and Wandsworth Council, London, UK; 3Public Health, Calderdale, UK; 4Northamptonshire County Cou...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2020-05-01
|
| Series: | ClinicoEconomics and Outcomes Research |
| Subjects: | |
| Online Access: | https://www.dovepress.com/budget-impact-analysis-of-the-introduction-of-injectable-prolonged-rel-peer-reviewed-article-CEOR |
| _version_ | 1818308046580875264 |
|---|---|
| author | Phillips-Jackson H Hallam C Cullen N Pearson T Gilman M Li L Musgrave P |
| author_facet | Phillips-Jackson H Hallam C Cullen N Pearson T Gilman M Li L Musgrave P |
| author_sort | Phillips-Jackson H |
| collection | DOAJ |
| description | Helen Phillips-Jackson,1 Clive Hallam,2 Niamh Cullen,3 Terry Pearson,4 Mark Gilman,5 Li Li,6 Paul Musgrave7 1Working Group on Innovation Assessment, Expert Faculty on Commissioning, London, UK; 2Richmond and Wandsworth Council, London, UK; 3Public Health, Calderdale, UK; 4Northamptonshire County Council, Northamptonshire, UK; 5Discovering Health, Manchester, UK; 6Applied Strategic, London, UK; 7Public Health, Cumbria, UKCorrespondence: Paul MusgravePublic Health, Cumbria, UKEmail commissioners@expertfaculty.orgObjective: To assess budget impact of the introduction of prolonged-release buprenorphine (PRB) for care of opioid use disorder (OUD) over 1 year in a defined population.Materials and Methods: A healthcare perspective, decision-tree model analysis of the cost of OUD care for a standard population was prepared to compare two scenarios: treatment of a population under the existing standard of care, or with the addition of PRB. The model assessed OUD-related direct costs (medication, delivery, psychosocial treatment), other services costs (harm reduction, general healthcare, social and justice services) and the impact of behaviors such as engaging with treatment and electing to use additional opioids “on top” of treatment regimens, and “dropping out” from treatment.Results: Standard population definition (persons offered OUD care services) is based on a typical administrative region in England with general population of 400,000 citizens, 1,777 high-risk opioid users requiring treatment and 909 patients initiating treatment in a year. The cost to provide OUD care for 1 year under the current scenario (70% treated with methadone, 30% sublingual buprenorphine) is £ 19.7M. In scenarios with increased PRB adoption/reduced sublingual buprenorphine or oral methadone use, the cost reduction ranges from £ 0.2M to 0.7M.Conclusion: The assessment showed a reduction of overall costs after introduction of PRB.Keywords: opioid use disorder, budget impact, pharmacotherapy, buprenorphine, methadone, injectable prolonged-release buprenorphine |
| first_indexed | 2024-12-13T07:08:03Z |
| format | Article |
| id | doaj.art-96ff3f416bbd478b93146bf19ce1cdf6 |
| institution | Directory Open Access Journal |
| issn | 1178-6981 |
| language | English |
| last_indexed | 2024-12-13T07:08:03Z |
| publishDate | 2020-05-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | ClinicoEconomics and Outcomes Research |
| spelling | doaj.art-96ff3f416bbd478b93146bf19ce1cdf62022-12-21T23:55:44ZengDove Medical PressClinicoEconomics and Outcomes Research1178-69812020-05-01Volume 1223324053582Budget Impact Analysis of the Introduction of Injectable Prolonged-Release Buprenorphine on Opioid Use Disorder Care Resource RequirementsPhillips-Jackson HHallam CCullen NPearson TGilman MLi LMusgrave PHelen Phillips-Jackson,1 Clive Hallam,2 Niamh Cullen,3 Terry Pearson,4 Mark Gilman,5 Li Li,6 Paul Musgrave7 1Working Group on Innovation Assessment, Expert Faculty on Commissioning, London, UK; 2Richmond and Wandsworth Council, London, UK; 3Public Health, Calderdale, UK; 4Northamptonshire County Council, Northamptonshire, UK; 5Discovering Health, Manchester, UK; 6Applied Strategic, London, UK; 7Public Health, Cumbria, UKCorrespondence: Paul MusgravePublic Health, Cumbria, UKEmail commissioners@expertfaculty.orgObjective: To assess budget impact of the introduction of prolonged-release buprenorphine (PRB) for care of opioid use disorder (OUD) over 1 year in a defined population.Materials and Methods: A healthcare perspective, decision-tree model analysis of the cost of OUD care for a standard population was prepared to compare two scenarios: treatment of a population under the existing standard of care, or with the addition of PRB. The model assessed OUD-related direct costs (medication, delivery, psychosocial treatment), other services costs (harm reduction, general healthcare, social and justice services) and the impact of behaviors such as engaging with treatment and electing to use additional opioids “on top” of treatment regimens, and “dropping out” from treatment.Results: Standard population definition (persons offered OUD care services) is based on a typical administrative region in England with general population of 400,000 citizens, 1,777 high-risk opioid users requiring treatment and 909 patients initiating treatment in a year. The cost to provide OUD care for 1 year under the current scenario (70% treated with methadone, 30% sublingual buprenorphine) is £ 19.7M. In scenarios with increased PRB adoption/reduced sublingual buprenorphine or oral methadone use, the cost reduction ranges from £ 0.2M to 0.7M.Conclusion: The assessment showed a reduction of overall costs after introduction of PRB.Keywords: opioid use disorder, budget impact, pharmacotherapy, buprenorphine, methadone, injectable prolonged-release buprenorphinehttps://www.dovepress.com/budget-impact-analysis-of-the-introduction-of-injectable-prolonged-rel-peer-reviewed-article-CEORopioid use disorderbudget impactpharmacotherapybuprenorphinemethadoneinjectable prolonged-release buprenorphine |
| spellingShingle | Phillips-Jackson H Hallam C Cullen N Pearson T Gilman M Li L Musgrave P Budget Impact Analysis of the Introduction of Injectable Prolonged-Release Buprenorphine on Opioid Use Disorder Care Resource Requirements ClinicoEconomics and Outcomes Research opioid use disorder budget impact pharmacotherapy buprenorphine methadone injectable prolonged-release buprenorphine |
| title | Budget Impact Analysis of the Introduction of Injectable Prolonged-Release Buprenorphine on Opioid Use Disorder Care Resource Requirements |
| title_full | Budget Impact Analysis of the Introduction of Injectable Prolonged-Release Buprenorphine on Opioid Use Disorder Care Resource Requirements |
| title_fullStr | Budget Impact Analysis of the Introduction of Injectable Prolonged-Release Buprenorphine on Opioid Use Disorder Care Resource Requirements |
| title_full_unstemmed | Budget Impact Analysis of the Introduction of Injectable Prolonged-Release Buprenorphine on Opioid Use Disorder Care Resource Requirements |
| title_short | Budget Impact Analysis of the Introduction of Injectable Prolonged-Release Buprenorphine on Opioid Use Disorder Care Resource Requirements |
| title_sort | budget impact analysis of the introduction of injectable prolonged release buprenorphine on opioid use disorder care resource requirements |
| topic | opioid use disorder budget impact pharmacotherapy buprenorphine methadone injectable prolonged-release buprenorphine |
| url | https://www.dovepress.com/budget-impact-analysis-of-the-introduction-of-injectable-prolonged-rel-peer-reviewed-article-CEOR |
| work_keys_str_mv | AT phillipsjacksonh budgetimpactanalysisoftheintroductionofinjectableprolongedreleasebuprenorphineonopioidusedisordercareresourcerequirements AT hallamc budgetimpactanalysisoftheintroductionofinjectableprolongedreleasebuprenorphineonopioidusedisordercareresourcerequirements AT cullenn budgetimpactanalysisoftheintroductionofinjectableprolongedreleasebuprenorphineonopioidusedisordercareresourcerequirements AT pearsont budgetimpactanalysisoftheintroductionofinjectableprolongedreleasebuprenorphineonopioidusedisordercareresourcerequirements AT gilmanm budgetimpactanalysisoftheintroductionofinjectableprolongedreleasebuprenorphineonopioidusedisordercareresourcerequirements AT lil budgetimpactanalysisoftheintroductionofinjectableprolongedreleasebuprenorphineonopioidusedisordercareresourcerequirements AT musgravep budgetimpactanalysisoftheintroductionofinjectableprolongedreleasebuprenorphineonopioidusedisordercareresourcerequirements |